Enanta Pharmaceuticals’ (ENTA) Buy Rating Reiterated at JMP Securities

JMP Securities reiterated their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) in a research report released on Tuesday, Stock Target Advisor reports. They currently have a $96.00 price objective on the biotechnology company’s stock.

Several other equities research analysts also recently weighed in on the company. Royal Bank of Canada cut their price objective on Enanta Pharmaceuticals from $65.00 to $54.00 and set a sector perform rating on the stock in a report on Tuesday. SVB Leerink boosted their target price on shares of Enanta Pharmaceuticals from $44.00 to $50.00 and gave the stock a market perform rating in a report on Monday, August 1st. StockNews.com initiated coverage on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 12th. They set a hold rating for the company. Finally, Oppenheimer lifted their price target on shares of Enanta Pharmaceuticals from $53.00 to $59.00 and gave the stock a market perform rating in a report on Wednesday, August 10th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of Hold and an average target price of $67.43.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA opened at $45.00 on Tuesday. The firm has a market cap of $932.85 million, a P/E ratio of -7.61 and a beta of 0.53. Enanta Pharmaceuticals has a twelve month low of $37.59 and a twelve month high of $92.90. The firm’s 50 day moving average price is $47.82 and its two-hundred day moving average price is $51.17.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last released its earnings results on Monday, November 21st. The biotechnology company reported ($1.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.10. Enanta Pharmaceuticals had a negative return on equity of 34.73% and a negative net margin of 141.31%. The business had revenue of $20.32 million for the quarter, compared to the consensus estimate of $22.86 million. During the same quarter in the previous year, the business earned ($1.22) earnings per share. Enanta Pharmaceuticals’s quarterly revenue was down 13.8% on a year-over-year basis. On average, sell-side analysts anticipate that Enanta Pharmaceuticals will post -2.99 earnings per share for the current fiscal year.

Institutional Trading of Enanta Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Signaturefd LLC lifted its stake in shares of Enanta Pharmaceuticals by 86.7% in the 1st quarter. Signaturefd LLC now owns 392 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 182 shares during the period. Nisa Investment Advisors LLC increased its holdings in Enanta Pharmaceuticals by 164.1% in the second quarter. Nisa Investment Advisors LLC now owns 1,207 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 750 shares in the last quarter. Captrust Financial Advisors lifted its stake in Enanta Pharmaceuticals by 343.8% in the first quarter. Captrust Financial Advisors now owns 852 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 660 shares during the period. Point72 Hong Kong Ltd boosted its holdings in shares of Enanta Pharmaceuticals by 83.7% during the 2nd quarter. Point72 Hong Kong Ltd now owns 1,565 shares of the biotechnology company’s stock worth $74,000 after buying an additional 713 shares in the last quarter. Finally, Quantbot Technologies LP boosted its holdings in shares of Enanta Pharmaceuticals by 13,411.8% during the 2nd quarter. Quantbot Technologies LP now owns 2,297 shares of the biotechnology company’s stock worth $108,000 after buying an additional 2,280 shares in the last quarter. Institutional investors own 97.09% of the company’s stock.

Enanta Pharmaceuticals Company Profile

(Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

See Also

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.